The new treatment with ozanimod (also known as zeposia) will benefit over 12,000 adults who suffer from moderate to severe active ulcerative colitis (UC).
Servier’s vorasidenib has shown efficacy in the treatment of low-grade glioma – a notoriously hard-to-treat form of brain cancer – although safety data has taken some of t
Health systems globally have reached a critical inflexion point, where ageing populations and tightening budgets mean we can no longer continue to purely treat late-stage symptomatic diseas